The U.S. Food and Drug Administration has postponed a crucial meeting of an advisory committee to consider a cheap version of a top-selling drug for rheumatoid arthritis and Crohn's disease, which had been scheduled for March 17. South Korean firm Celltrion and its partner Hospira want to sell Remsima in the United States as a cut-price copy of Johnson & Johnson and Merck & Co's branded drug Remicade. The FDA said a future meeting date would be announced in due course. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment